Aimmune’s peanut allergy drug hits PhIII trials

21st February 2018 Uncategorised 0

A Phase III trial assessing Aimmune Therapeutics’ experimental peanut allergy drug AR101 has hit its primary targets.

More: Aimmune’s peanut allergy drug hits PhIII trials
Source: News